BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 8385286)

  • 1. Enhanced platelet reactivity with erythropoietin but not following transfusion in dialysis patients.
    Roger SD; Piper J; Tucker B; Raine AE; Baker LR; Kovacs IB
    Nephrol Dial Transplant; 1993; 8(3):213-7. PubMed ID: 8385286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erythropoietin for anaemia in haemodialysis patients: results of a maintenance study (the Canadian Erythropoietin Study Group).
    Muirhead N; Laupacis A; Wong C
    Nephrol Dial Transplant; 1992; 7(8):811-6. PubMed ID: 1325613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of recombinant human erythropoietin in critically ill patients admitted to a long-term acute care facility: a randomized, double-blind, placebo-controlled trial.
    Silver M; Corwin MJ; Bazan A; Gettinger A; Enny C; Corwin HL
    Crit Care Med; 2006 Sep; 34(9):2310-6. PubMed ID: 16878035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of recombinant human erythropoietin (rHuEpo) on the hemostatic system in chronic hemodialysis patients.
    Huraib S; al-Momen AK; Gader AM; Mitwalli A; Sulimani F; Abu-Aisha H
    Clin Nephrol; 1991 Nov; 36(5):252-7. PubMed ID: 1752076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
    Nakamoto H; Mimura T; Honda N
    Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced blood transfusions requirements after allogeneic bone marrow transplantation: results of a randomised, double-blind study with high-dose erythropoietin.
    Klaesson S; Ringdén O; Ljungman P; Lönnqvist B; Wennberg L
    Bone Marrow Transplant; 1994 Apr; 13(4):397-402. PubMed ID: 8019463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of human recombinant erythropoietin (rhuEPO) on platelet phospholipids in chronically hemodialysed].
    Krawczyk W; Dmoszyńska A; Ledwozyw A; Soroka-Wojtaszko M
    Acta Haematol Pol; 1993; 24(4):327-31. PubMed ID: 8303978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant human erythropoietin therapy after allogeneic hematopoietic cell transplantation with a nonmyeloablative conditioning regimen: low donor chimerism predicts for poor response.
    Vanstraelen G; Baron F; Willems E; Bonnet C; Hafraoui K; Frère P; Fillet G; Beguin Y
    Exp Hematol; 2006 Jul; 34(7):841-50. PubMed ID: 16797411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2004 Japanese Society for Dialysis Therapy guidelines for renal anemia in chronic hemodialysis patients.
    Gejyo F; Saito A; Akizawa T; Akiba T; Sakai T; Suzuki M; Nishi S; Tsubakihara Y; Hirakata H; Bessho M;
    Ther Apher Dial; 2004 Dec; 8(6):443-59. PubMed ID: 15663544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effectiveness of recombinant human erythropoietin in the treatment of transfusion-dependent anemia in patients on chronic dialysis].
    Graf H; Mayer G; Cada EM; Thum J; Stummvoll HK
    Wien Klin Wochenschr; 1987 Dec; 99(24):855-9. PubMed ID: 3439185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Evaluation of treating anemia in patients undergoing chronic dialysis with small doses of human recombinant erythropoietin].
    Marusza W; Matuszkiewicz-Rowińska J; Tomik Z; Andrzejewski A; Rokicka M; Paszkowska M; Drygieniec D; Bobilewicz D; Zawadzka M; Abbas-Fatah A
    Pol Tyg Lek; 1995 Oct; 50(40-44):15-8, 31. PubMed ID: 8650050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evaluation of platelet function during treatment with recombinant human erythropoietin (r-HuEPO) in patients hemodialyzed and dialyzed peritoneally].
    Janicka L; Majdan M; Dmoszyńska A; Ksiazek A; Berger B; Baranowska E
    Wiad Lek; 1993 Oct; 46(19-20):756-60. PubMed ID: 7975620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does additional treatment with fish oil mitigate the side effects of recombinant human erythropoietin in dialysis patients?
    de Fijter CW; Popp-Snijders C; Oe LP; Tran DD; van der Meulen J; Donker AJ
    Haematologica; 1995; 80(4):332-4. PubMed ID: 7590502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of recombinant human erythropoietin on erythropoiesis in homozygous sickle-cell anaemia and renal failure.
    Tomson CR; Edmunds ME; Chambers K; Bricknell S; Feehally J; Walls J
    Nephrol Dial Transplant; 1992; 7(8):817-21. PubMed ID: 1325614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant human erythropoietin therapy is very effective after an autologous peripheral blood stem cell transplant when started soon after engraftment.
    Baron F; Frère P; Fillet G; Beguin Y
    Clin Cancer Res; 2003 Nov; 9(15):5566-72. PubMed ID: 14654537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of recombinant human erythropoietin on antiplatelet action of aspirin and clopidogrel in healthy subjects: results of a double-blind, placebo-controlled randomized trial.
    Tang YD; Rinder HM; Katz SD
    Am Heart J; 2007 Sep; 154(3):494.e1-7. PubMed ID: 17719296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of recombinant human erythropoietin on hematological and hemostatic parameters with special reference to microhemolysis.
    Maurin N; Fitzner S; Fritz H; Gladziwa U; H agel J; Stefanidis I
    Clin Nephrol; 1995 Mar; 43(3):196-200. PubMed ID: 7774078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predialysis versus postdialysis hematocrit evaluation during erythropoietin therapy.
    Movilli E; Pertica N; Camerini C; Cancarini GC; Brunori G; Scolari F; Maiorca R
    Am J Kidney Dis; 2002 Apr; 39(4):850-3. PubMed ID: 11920353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
    Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
    Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
    Provenzano R; Besarab A; Macdougall IC; Ellison DH; Maxwell AP; Sulowicz W; Klinger M; Rutkowski B; Correa-Rotter R; Dougherty FC;
    Clin Nephrol; 2007 May; 67(5):306-17. PubMed ID: 17542340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.